On September 6, 2026, Vigonvita Life Sciences Co., Ltd. (2630.HK) received the “2026 Technology Innovation Golden Bull Award” at the 2026 Xiamen Sci-Tech Innovation and Securities Industry Development Conference. The award reflects the capital market’s strong recognition of Vigonvita’s R&D and innovation capabilities as well as its growth prospects. The conference was hosted by China Securities Journal, organized by China News Development Co., Ltd. Fujian Branch, and received comprehensive strategic support from Xiamen Jinyuan Investment Group Co., Ltd.
In the first half of 2026, Vigonvita delivered an impressive performance: revenue reached RMB 132 million, representing a year-on-year increase of 693.7%, while gross margin further rose to 89.4%. The initial commercial scale-up of Onvita® has shown encouraging results, instilling confidence and momentum in the market and the industry.
In R&D and innovation, Vigonvita has built a multi-tiered innovative drug pipeline spanning from preclinical to late-stage clinical development. In addition to Minnovi® (VV116), which has already entered the commercial stage and continues to generate cash flow for the company, the pipeline now also includes Onvita®, a highly potent and selective PDE5 inhibitor with a novel chemical structure. Clinical studies have demonstrated that Onvita® exhibits significant efficacy and a favorable safety profile for the treatment of erectile dysfunction, with broad applicability across diverse patient populations and usage scenarios, positioning it as a potential “Best in Class” drug. The pipeline further comprises multiple candidate drugs currently in Phase III and Phase II clinical trials. Among them, the Phase III trial of VV116 for respiratory syncytial virus (RSV) infection is ongoing, and a Phase II trial for Nipah virus infection has been approved. Clinical trials for other candidates, including LV232, VV913, and VV119, are progressing steadily as planned. This pipeline layout—spanning multiple therapeutic areas, indications, and development stages—endows Vigonvita with the resilience and foundational strength to navigate R&D cycles and mitigate single-product risks, thereby laying a solid foundation for sustained and rapid performance growth.
Looking ahead, Vigonvita will continue to uphold its innovation-driven development philosophy, with a deep focus on viral infections, neuropsychiatric disorders, and reproductive health. The company remains committed to relieving patients’ suffering, creating value for society, and contributing to the nation.